The CRISPR community is facing a tsunami of data but a dearth of computational tools required for their analyses. By empowering the researcher, Latch is helping remove a significant bottleneck that is currently slowing down the CRISPR research cycle, enabling the discovery of new therapies.
Nulla adipisicing do ut aliquip elit tempor fugiat. Mollit est exercitation excepteur ea consequat ullamco Lorem ex id. Ipsum nostrud Lorem dolor nisi do est in ex amet eu nostrud. Amet commodo consectetur enim nostrud dolore sint excepteur irure aliqua consectetur. Veniam occaecat et enim eiusmod qui fugiat eiusmod eiusmod laborum exercitation veniam ipsum velit. Ut veniam cupidatat ea tempor ad ad exercitation amet qui. Esse commodo sint deserunt ut elit minim sint. Amet laborum ut adipisicing minim sunt cillum anim in est ipsum aliquip anim in tempor pariatur.
Infrastructure Computer Science
Progressing Science Knowledge
Lux investment: 2021
Alfredo Andere
Kenny Workman
Kyle Giffin
Latch Bio
Similar companies
Hugging Face is on a mission to advance and democratize Natural Language Processing.
Infrastructure Computer Science
Progressing Science Knowledge
Increasing Productivity Efficiency
Lux investment: 2019
Clément Delangue
Julien Chaumond
Eikon Therapeutics is pioneering a new method of drug discovery based on tracking and measuring the movement of individual proteins in living cells.
Biology Biochemistry
Advancing Human Health
Progressing Science Knowledge
Lux investment: 2019
Eric Betzig
Robert Tjian
Luke Lavis
Xavier Darzacq
Databricks unifies all your data, analytics, and AI on one platform.
Infrastructure Computer Science
Lux investment: 2023
Ali Ghodsi
Ion Stoica
Matei Zaharia
Andy Konwinski
Patrick Wendell
Reynold Xin
Andy Konwinski
Arsalan Tavakoli-Shiraji
Applied Intuition provides software infrastructure to safely develop, test and deploy autonomous vehicles at scale.
Engineering Electronics
Infrastructure Computer Science
Increasing Productivity Efficiency
Lux investment: 2017
Qasar Younis
Peter Ludwig
Recursion Pharma is combining high-throughput experimental biology, bioinformatics, and machine learning to rapidly identify new indications for many known drugs and shelved assets. The company completed its IPO [NASDAQ: RXRX] in 2021.
Biology Biochemistry
Advancing Human Health
Progressing Science Knowledge
Lux investment: 2016
IPO: 2021
Chris Gibson, PhD
Blake Borgeson, PhD
Dean Li, PhD